neuroendocrine%20tumors
NEUROENDOCRINE TUMORS
Neuroendocrine tumors are rare, small, slow-growing epithelial neoplasms with predominant neuroendocrine differentiation found in most organs of the body.
They arise from cells throughout the diffuse endocrine system.
Carcinoid tumors and pancreatic neuroendocrine tumors are the most common.
Carcinoid tumors arise from the lungs & bronchi, stomach, small intestine, appendix, rectum or thymus.
Majority of the neuroendocrine tumors are sporadic but some tumors are caused by inherited genetic syndromes such as multiple endocrine neoplasia, Von-Hippel Lindau disease, tuberous sclerosis complex and neurofibromatosis.
They have the ability to store and secrete various peptides and neuroamines.

Neuroendocrine%20tumors Management

Follow Up

  • NETs are slow growing but they may progress faster if they are poorly differentiated or have a high Ki67 index > 5%
  • Patients should be monitored more closely during the first year after diagnosis to determine the status of the disease
    • Assess clinical manifestations, biomarkers, presence of new sites of disease, & quality of life during treatment
    • Routine evaluations, such as echocardiogram for patients with elevated 5-HIAA, to detect carcinoid heart disease in its early stages can improve prognosis
  • PET scan & somatostatin scintigraphy are not advised for routine surveillance
  • It is recommended to have re-evaluation of the patient 3-12 months after surgical resection or earlier if the patient is symptomatic
    • >1 year following surgical resection, every 6-12 months is recommended schedule for follow-up
    • Abdominal or pelvic multiphasic CT or MRI, gastrin, CgA & 5-HIAA levels may be used for disease monitoring
  • Low-risk patients (eg carcinoid tumor of the appendix) usually require no follow-ups
    • Low-risk patients are those having <2 cm primary tumor (<1 cm for rectal tumors), no nodal involvement & have low Ki67 < 5%
  • Repeat rectal MRI or endoscopic ultrasound 6-12 months after initial treatment is recommended for rectal NETs 1-2 cm in size & for gastric NETs type 1 or 2 for the 1st 3 months then annually if negative for pathologies
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Audrey Abella, 6 days ago
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.